enteric hyperoxaluria

hyperoxaluria

 [hi″per-ok″sah-lu´re-ah]
an excess of oxalates in the urine, which can lead to formation of kidney stones. Called also oxaluria.
enteric hyperoxaluria formation of calcium oxalate calculi in the urinary tract, occurring after extensive resection or disease of the ileum, due to excessive absorption of oxalate from the colon.
primary hyperoxaluria an autosomal recessive disorder characterized by urinary excretion of oxalate, with nephrolithiasis, nephrocalcinosis, early onset of renal failure, and often a generalized deposit of calcium oxalate.

enteric hyperoxaluria

Hyperoxaluria caused by disease or surgical removal of the ileum.
See also: hyperoxaluria
References in periodicals archive ?
Use of a probioitic to decrease enteric hyperoxaluria.
an oxalate decarboxylase, for the treatment of oxalate malabsorption and kidney failure in enteric hyperoxaluria.
32) Enteric hyperoxaluria resulting from chronic steatorrhea can be seen in patients with inflammatory bowel disease, pancreatic insufficiency, or following bowel surgery.
We concluded that the patient had enteric hyperoxaluria due to excess oxalate absorption in his colon leading to subsequent excretion in his urine.
This disorder is distinct from enteric hyperoxaluria, which results from hyperabsorption of oxalate from the digestive tract [5].
Together with the company program investigating enteric hyperoxaluria, this announcement bolsters the Company's position as a leader in developing therapy for hyperoxaluria, a debilitating condition that leads to kidney damage and end-stage renal disease, if untreated.
ALTU-237 is being developed as an oral form of an oxalate-degrading enzyme for the treatment of primary hyperoxaluria and enteric hyperoxaluria, as well as to prevent the recurrence of kidney stones.
ALTU-237 is an oral form of an oxalate-degrading enzyme for the treatment of primary hyperoxaluria and enteric hyperoxaluria, as well as to prevent the recurrence of kidney stones.
ALTU-237, Altus Pharmaceuticals' lead pre-clinical product candidate, is an orally-delivered crystalline formulation of an oxalate-degrading enzyme that Altus designed for the treatment of primary hyperoxaluria and enteric hyperoxaluria, as well as the prevention of recurrent kidney stones in individuals with a high risk or history of kidney stones.
Achieved pre-clinical proof-of-concept for ALTU-237, an orally-administered crystalline formulation of an oxalate-degrading enzyme which is designed for the treatment of primary hyperoxaluria and enteric hyperoxaluria, as well as to prevent the recurrence of kidney stones in individuals with a risk or history of recurrent kidney stones.
We believe that our approach has the potential of enhancing the quality of life of many who suffer from oxalate-related conditions, including primary hyperoxaluria, kidney stones, enteric hyperoxaluria, and cystic fibrosis," said Dr.